Owner Scorecard


← All companies ← VMI Manual VNO → ← UTHR Pharmaceuticals VRDN →

VNDA, Vanda Pharmaceuticals Inc.

Pharmaceuticals consumer brand Cyclical

Vanda Pharmaceuticals Inc. is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients.

HETLIOZ is the first product approved by the United States Food and Drug Administration (FDA) for patients with Non-24 and for patients with SMS.

Latest annual: FY2025 10-K
VNDA · Vanda Pharmaceuticals Inc.
I

The business

What it sells, where the money comes from, the kind of company it is.

Revenue · FY2025
$216M
+8.7% YoY · −3% 5-yr CAGR
Vital signs · TTM, with 5-yr average
Revenue $216M 5-yr avg $226M
Operating margin −86.1% 5-yr avg −15.9%
ROIC −89% 5-yr avg −10%
Owner-earnings margin −66% 5-yr avg −3%
Free cash flow margin −66% 5-yr avg −3%

Next report By 11/8 · the 10-Q for the quarter ended late September · due within 40 days of period end · has filed ~37 days after · the wire records it on arrival

The business in brief

read the 10-K →

What this business is and what moves its needle, from its own SEC filings.

What it is
Revenue is Fanapt (54%), Hetlioz (33%) and PONVORY (13%).
Situation
Cyclical. Margins collapse and recover repeatedly across the record; a single year, good or bad, misstates the through-cycle earning power.
What moves the needle
Operating margin has reached 16% at its best but run negative through the cycle (median −2.4%) — so the question is which reading is truer: whether the median was pulled below zero by one-off charges, by the cycle, or by spending it is still growing into, and whether it settles back at a profit. Stock-based pay runs about 5.9% of sales, a real and recurring claim on owners that the GAAP margin understates. Read this kind of business on the pipeline against the patent cliff, and pricing. On its own account, the filing leans hardest on pricing power & competition, set against the numbers in what the filing emphasizes, below.
Is it a good business?
Return on capital has rarely cleared the cost of capital (median −0%, above 15% in 0 of 10 years). By owner earnings: roughly 9% of revenue reaches owners as cash, though it swings. The cycle and the balance sheet decide this one; the worst year tells more than the median, and the rest is in the 10-K.

Every line is arithmetic on the company's filings, shown in full in the sections below.

Where the money comes from

read the 10-K →

Revenue spreads across 3 lines, the largest Fanapt at 54%.

Revenue by product line, FY2025
  • Fanapt54%$117M
  • Hetlioz33%$71M
  • PONVORY13%$27M

From the segment footnote of the company's own 10-K. Shares are of total revenue; the profit bar shows each segment's share of segment operating profit, before unallocated corporate costs.

II

The record

Ten years of arithmetic, read across the cycle.

The record, 2016–2025

realized figures from each filing · older years to the left
2016’162017’172018’182019’192020’202021’212022’222023’232024’242025’25TTMTTMJun 2026
Income statement
$146M$165M$193M$227M$248M$269M$254M$193M$199M$216M$216MRevenueRevenue
68%75%55%57%57%46%54%59%74%110%122%SG&A / revenueSG&A/rev
20%23%23%21%22%28%34%40%37%51%54%R&D / revenueR&D/rev
($19M)($17M)$22M$23M$27M$42M$6M($14M)($41M)($151M)($186M)Operating incomeOp. inc.
−12.7%−10.2%11.3%10.0%11.0%15.7%2.5%−7.2%−20.5%−70.0%−86.1%Operating marginOp. mgn
($18M)($15M)$25M$29M$32M$42M$11M$6M($23M)($139M)Pretax incomePretax
($18M)($16M)$25M$116M$23M$33M$6M$3M($19M)($220M)($275M)Net incomeNet inc.
1%26%22%44%Effective tax rateTax rate
Cash flow & returns
($8M)($2M)$30M$46M$52M$64M$32M$13M($16M)($109M)($142M)Operating cash flowOp. cash
$935K$1M$1M$1M$1M$1M$1M$920K$859K$1M$1MDepreciationDeprec.
$429K$2M($8M)($84M)$14M$14M$8M($5M)($10M)$100M$122MWorking capital & otherWC & other
$1M$2M$368K$1M$2M$552K$679K$383K$490K$998K$674KCapexCapex
1.0%1.0%0.2%0.4%0.7%0.2%0.3%0.2%0.2%0.5%0.3%Capex / revenueCapex/rev
($9M)($3M)$30M$45M$50M$64M$31M$12M($16M)($110M)($143M)Owner earningsOwner earn.
−6.2%−1.9%15.3%19.8%20.3%23.7%12.3%6.4%−8.2%−51.1%−66.3%Owner earnings marginOE mgn
($10M)($4M)$30M$45M$50M$64M$31M$12M($16M)($110M)($143M)Free cash flowFCF
−6.5%−2.2%15.3%19.8%20.1%23.7%12.3%6.4%−8.2%−51.1%−66.3%Free cash flow marginFCF mgn
($10M)($10M)($110M)($68M)($41M)($77M)$50M($12M)($17M)$95MInvesting cash flowInv. cash
$8M$5M$107M$6M$6M$4M$734K$0($155K)($3M)Financing cash flowFin. cash
$5K$42K($38K)($1K)$53K($91K)$265K$47K($163K)$23KExchange-rate effectFX
($10M)($7M)$27M($16M)$16M($9M)$83M$792K($34M)($17M)Change in cashΔ cash
-16%-14%10%6%5%7%1%-2%-7%-49%-89%ROICROIC
-14%-12%9%28%5%7%1%0%-4%-67%-125%Return on equityROE
−14%−12%9%28%5%7%1%0%−4%−67%−125%Retained to equityRetained/eq
Balance sheet
$40M$34M$61M$45M$61M$52M$135M$136M$102M$85M$56MCash & investmentsCash+inv
$20M$18M$29M$26M$30M$32M$34M$34M$47M$55M$60MReceivablesReceiv.
$779K$840K$994K$1M$1M$1M$1M$1M$2M$2M$2MInventoryInvent.
$16M$20M$22M$28M$32M$34M$46M$38M$39M$68M$8MAccounts payablePayables
$5M($2M)$8M($83K)($193K)($946K)($11M)($3M)$10M($12M)$53MOperating working capitalOper. WC
$174M$170M$299M$354M$409M$478M$519M$433M$439M$347M$264MCurrent assetsCur. assets
$50M$70M$53M$60M$66M$74M$91M$88M$100M$145M$164MCurrent liabilitiesCur. liab.
3.5×2.4×5.6×6.0×6.2×6.4×5.7×4.9×4.4×2.4×1.6×Current ratioCurr. ratio
$5M$5M$4M$4M$4M$3M$3M$2M$2M$2MNet PP&ENet PP&E
$210M$205M$332M$484M$533M$594M$634M$648M$656M$489M$412MTotal assetsAssets
($40M)($34M)($61M)($45M)($61M)($52M)($135M)($136M)($102M)($85M)($56M)Net debt / (cash)Net debt
$79M$74M$57M$73M$80M$89M$107M$104M$118M$162MTotal liabilitiesTotal liab.
$131M$131M$275M$411M$453M$505M$527M$545M$539M$327M$220MShareholders’ equityEquity
5.9%6.3%6.0%5.9%5.4%5.7%6.4%7.3%6.3%4.4%4.2%Stock comp / revenueSBC/rev
Per share
43.4M44.7M53.0M54.8M55.2M56.9M57.0M57.6M58.1M58.9M59.8MShares out (diluted)Shares
$3.36$3.69$3.64$4.14$4.50$4.72$4.46$3.35$3.42$3.67$3.60Revenue / shareRev/sh
$-0.41$-0.35$0.48$2.11$0.42$0.58$0.11$0.04$-0.33$-3.74$-4.59EPS (diluted)EPS
$-0.21$-0.07$0.56$0.82$0.91$1.12$0.55$0.22$-0.28$-1.87$-2.39Owner earnings / shareOE/sh
$-0.22$-0.08$0.56$0.82$0.91$1.12$0.55$0.22$-0.28$-1.87$-2.39Free cash flow / shareFCF/sh
$0.03$0.04$0.01$0.02$0.03$0.01$0.01$0.01$0.01$0.02$0.01Cap. spending / shareCapex/sh
$3.02$2.94$5.19$7.49$8.21$8.87$9.25$9.47$9.26$5.55$3.68Book value / shareBVPS
Per-share growththe realized rate an owner's share compounded
9-yr5-yr
Revenue / share+1.0%/yr−4.0%/yr
Capital spending / share−6.9%/yr−12.2%/yr
Book value / share+7.0%/yr−7.5%/yr

The year, in the company's words

the filing →

Verbatim from the 10-K's management discussion. Each sentence is shown only because its subject, direction, and stated figures check out against the filed numbers on this page. The words are the company's; the arithmetic is the record's.

  • Hetlioz-6.8%
    “HETLIOZ® net product sales decreased by $5.2 million, or 7%, to $71.4 million for the year ended December 31, 2025 compared to $76.7 million for the year ended December 31, 2024. The decrease to net product sales was attributable to a decrease in volume and price, net of deductions.”
    ✓ figure matches the filed record

Where the cash went

ReinvestBuybacksDividendsAcquisitionsRetained

Each year's operating cash, by what management did with it: the mix, and how it drifts.

FY2018FY2023

Net income is the accountant's number; owner earnings is the cash an owner could take out. The walk between them, off the cash-flow statement, and whether the gap is widening or holding.

In fiscal 2025 the business turned a $220M loss into ($110M) of owner earnings: more cash than the profit line showed, after the non-cash charges and the capital it put back in.

FY2025FY2024FY2023FY2022FY2021
Reported net income($220M)($19M)$3M$6M$33M
Depreciationnon-cash charge added back+$1M+$859K+$920K+$1M+$1M
Amortization of intangible assetsnon-cash charge added back; the purchase price of past acquisitions, expensed over time+$7M+$7M+$2M+$2M+$1M
Stock-based compensationreal costnon-cash, but a real cost+$9M+$12M+$14M+$16M+$15M
Working capital & othertiming of cash in and out, other non-cash items+$93M−$17M−$7M+$7M+$13M
Cash from operations($109M)($16M)$13M$32M$64M
Capital expenditurecash put back in to keep running and to grow−$998K−$490K−$383K−$679K−$552K
Owner earnings($110M)($16M)$12M$31M$64M
Owner-earnings marginowner earnings ÷ revenue-51%-8%6%12%24%

Owner earnings is the cash an owner could pull out without starving the business: operating cash less the capital it must spend to hold its position . The cash-flow statement also adds stock comp back as non-cash, but it is a real cost paid in shares; counted as the expense it is (less $9M), owner earnings is nearer ($120M).

Maintenance capex is estimated as depreciation where a growing business invests above it; free cash flow is the figure the scorecard's free-cash margin reads.

III

Quality & stewardship

Returns, the balance sheet, capital allocation, and pay.

Owner’s Scorecard

FY2025 10-K · source on SEC EDGAR →

Will it survive?

  • No meaningful interest burden
    Little or no interest expense reported
    What this means

    Little or no interest expense reported, the business isn't leaning on lenders to operate.

  • Net cash, debt-free
    Cash $85M − debt $0
    What this means

    Cash and short-term investments exceed every dollar of debt by $85M, on net the company owes nothing, and can act from strength when others can't. Net debt is the leverage figure that matters: the cash is already set against the debt. Strategic or illiquid investments aren't counted here.

  • Not enough data
    What this means

    The filing data didn't include the inputs for this check.

Is it a good business?

  • Not enough data
    Industry peers: median -59%
    What this means

    The filing data didn't include the inputs for this check.

  • Solid through the cycle
    10-yr median margin, range -51%–24%; latest ($110M) = operating cash ($109M) − maintenance capex $998K
    Industry peers: median -132%
    What this means

    What an owner could take out without starving the business: operating cash less the maintenance capital it must spend to hold its position — Buffett's owner earnings. That's -51% of revenue this year, a 9% median across 10 years. Treating stock comp as the real expense it is (less $9M of SBC) leaves ($120M).

  • Loss, and burning cash
    Net income ($220M) · cash from operations ($109M)
    What this means

    The company reported a net loss, so a conversion ratio isn't meaningful. What matters then is whether operations still threw off cash, here, they did not.

How is the cash used?

  • Not enough data
    What this means

    The filing data didn't include the inputs for this check.

  • Investing or harvesting? 0.90×
    Maintaining
    Capex $998K ÷ property depreciation $1M
    What this means

    Descriptive, not a grade. Above ~1× means investing faster than assets wear out (growth, or, sustained for years, today's earnings carrying less depreciation than tomorrow's will). Below means spending less than it's wearing out (efficiency, or a melting asset base). The ratio won't tell you which; the filings will.

The promise and the pay packet

  • Is the buyback buying ownership, or mopping up? 4.4%
    The count is rising
    Stock compensation $9M (fiscal 2025), 4.4% of revenue · no repurchases · diluted shares +3.4% since 2022
    What this means

    Stock handed to employees is a real cost paid in the owner's own currency: it is charged against profit, but the shares it creates are permanent. Many companies repurchase stock at the same time, which looks like a return of capital and often is not — if the count barely moves, the cash merely cancelled the pay packet and bought the owner nothing. The three states worth telling apart are a count genuinely shrinking, a count standing still despite large repurchases, and a count rising because the issuance was never offset at all.

Graham’s defensive tests · 1 of 3 met

Graham’s numerical criteria for the defensive investor (The Intelligent Investor, ch. 14), run on the filings. A floor of safety, not a buy signal; many fine modern businesses fail his strictest liquidity rules by design.

  • Adequate size Miss
    Revenue ≥ $2B · $216M
    What this means

    Big enough to weather a storm. Graham's 1972 floor was ~$100M of sales (≈ $700M today); we use a $2B revenue line as a conservative modern stand-in.

  • Strong liquidity Pass
    Current ratio ≥ 2× · 2.39×
    What this means

    Current assets at least twice current liabilities, near-term bills covered without touching the business. Strict by design: many cash-rich modern firms run leaner and miss it, holding their cushion in longer-dated securities.

  • Earnings stability Miss
    A profit every year (10-yr record) · 4 loss years
    What this means

    Graham wanted earnings in each of the past ten years, the stability a defensive owner leans on.

  • Dividend record
    Uninterrupted dividends · no dividend line tagged in the data
    What this means

    An unbroken dividend was Graham's mark of durability. This record carries no dividends-paid line in any year — common for partnerships, whose distributions file under tags the chain doesn't read — so the criterion is withheld rather than judged on silence.

  • Earnings growth
    Earnings +33% over the record ·
    What this means

    Earnings were negative early in the record, a growth rate isn't meaningful.

  • Moderate price
    P/E ≤ 15 and P/E × P/B ≤ 22.5 · decided by the price
    What this means

    Graham's valuation gate, the wall he kept between a sound business and a sound investment. Three-year average earnings are $-1.31/share (latest year $-3.65), the averaged base the calculator's gate runs on, and book value is $5.41/share. Enter a price in “What the price implies” just below for the P/E, P/B, and whether it clears. But this is the rule Buffett outgrew: there's no hard P/E law, and a wonderful business can deserve a far richer multiple if the thesis holds, treat it as the bargain-hunter's floor, not a verdict on the price.

Durability & moat, 2016–2025

Whether the record’s returns held, and what the capital reinvested earned.

  • Profitable years 6 of 10
    What this means

    Lost money in 4 year(s), look at what happened there before trusting the average.

  • Operating margin −4% → −33% (3-yr avg ends)
    What this means

    Through the cycle the operating margin slipped — about −4% early to −33% lately, median −7% — competition or costs are biting in.

  • Worst year 2025 · −70.0% op. margin
    What this means

    Operations went underwater in 2025, understand why before trusting the good years.

  • Share count +3.4%/yr
    What this means

    The share count is rising, dilution works against you on a per-share basis.

All figures as filed; the source filing is linked above.

Current Position

as of the latest quarter, Jun 30, 2026

Can the business pay what it owes this year, off the freshest balance sheet: the quality of the assets, the debt actually coming due, and what a low ratio means here.

Current assets$264M
  • Cash & short-term investments$56M
  • Receivables$60M
  • Inventory$2M
  • Other current assets$147M
Current liabilities$164M
  • Accounts payable$70M
  • Other current liabilities$94M
Current ratio1.61×all current assets ÷ what's due · Graham looked for 2×
Quick ratio1.60×stricter: inventory excluded
Cash ratio0.34×strictest: cash alone against what's due
Working capital$100Mthe cushion left after near-term bills
Cash runway0.4 yrsthe business is consuming cash; this is how long the cash on hand lasts at that rate
Revenue, latest quarter vs. a year ago−3.9%the freshest read on whether the business is still growing
Current ratio, recent quarters4.9× → 1.6×
Deeper floors
Tangible book value$107Mequity stripped of goodwill & intangibles
Net current asset value$72MGraham's net-net: current assets less all liabilities
Debt incl. operating leases$16M$16M of it operating leases

From the company's latest filing.

How the cash was used, 2016–2025

Over the record, the business generated $101M of operating cash; how management split it reads as a balanced allocator, splitting cash between the business, owners, and the balance sheet.

  • Reinvested$9M · 9%
  • Retained (debt / cash)$92M · 91%
  • Net change in share count37.7%

    The diluted count rose from 43M to 60M: issuance (stock pay, deals) outran any buybacks, so owners were diluted on net.

  • Dividend record

    No dividend line was reported in the filing data over the span; the record here neither confirms nor rules out a payout.

Buybacks are gross of stock issued to staff; the share-count line above is the net of that, the figure that decides whether owners gained. The average price paid blends a year of purchases (and any accelerated repurchase), so it is close, not exact. The record of where the cash went and on what terms.

Management, ownership & pay

read the proxy →

From the proxy: how much of the business the people running it own, and how they are paid, beside what the business earned for its owners in the same years.

Fiscal yearChief executivePay, as filed“Actually paid”Owner earnings
2021Dr. Mihael H. Polymeropoulos$6.2M$5.6M$64M
2022Dr. Mihael H. Polymeropoulos$4.3M$860k$31M
2023Dr. Mihael H. Polymeropoulos$3.7M$1.8M$12M
2024Dr. Mihael H. Polymeropoulos$3.9M$4.3M($16M)
2025Dr. Mihael H. Polymeropoulos$3.9M$7.6M($110M)

Both pay figures are the company’s own, from the pay-versus-performance table its proxy statement files. “As filed” is the Summary Compensation Table total: salary, bonus, and equity awards at their value on the day of grant. “Actually paid” is the SEC’s prescribed recalculation, which re-marks those equity awards to what they became as they vested; it can swing far above or below the filed figure in either direction, and negative years occur. Owner earnings are the whole business's, from the record above, for the same fiscal years.

  • Insider ownership10.7%

    The stake all directors and executive officers hold together, per the 2026 proxy: skin in the game, the first thing Munger reads.

  • Stock-based compensation$9M

    The slice of the business handed to employees in shares in fiscal 2025, 4.4% of revenue. Buffett's oldest accounting fight: this is compensation, compensation is an expense, real whether or not the headline earnings admit it. One trap: the cash-flow statement adds SBC back, so the operating cash, and the owner earnings drawn from it, are flattered by exactly this amount; counted as the cost it is, what an owner keeps is lower.

Peers, Pharmaceuticals

The same industry, side by side on owner economics. Each column names the period it is read over, and a median resting on fewer than three years carries that count beside it; the group median at the foot is the line to read each figure against.

CompanyRevenuelatest FY, USDGross marginmedian over the recordOp. marginmedian over the recordROICmedian over the recordOwner earn. marginmedian over the record
RCUSArcus Biosciences Inc.$247M-204.5%-55%-132%
AKBAAkebia Therapeutics Inc.$236M62%-42.3%-116%-31%
ANABAnaptysBio Inc.$235M-60.9%-25%-64%
PBYIPuma Biotechnology Inc$228M76%5.5%-59%8%
IDYAIDEAYA Biosciences Inc.$219M-179.9%-22%-175%
VNDAVanda Pharmaceuticals Inc.$216M-2.4%-0%9%
RYTMRhythm Pharmaceuticals Inc.$190M90%-221.1%4y-67%-132%4y
STOKStoke Therapeutics Inc.$184M-277.3%-79%-238%
Group median-120.4%-57%-98%
IV

The price

What a price has to assume.

What the price implies

reverse-DCF

Type today's close and see the owner-earnings growth you'd have to believe to justify it, beside what Vanda Pharmaceuticals Inc. has delivered.

Vanda Pharmaceuticals Inc.’s latest year shows negative owner earnings, a cyclical trough. So the tool opens on the through-cycle base, the cash it would earn at rest; clear the toggle below to read the latest year exactly as reported.

$

Through the cycle, Vanda Pharmaceuticals Inc. earns about $20M on its 9.4% median owner-earnings margin. This year’s −51.1% margin runs below that; the reported figure may understate a lean year. Normalize, below, values the price on that through-cycle figure rather than the latest year.

Base

The assumptions

9.0% = the 4.71% 10-year Treasury (Aug 18, 2026) + 4.29 points of equity premium. The rate you require is yours to set.

Enter a price above to run it.

Implied by the price
Owner-earnings growth, delivered
Owner-earnings yield
P/E (3-yr earnings ’23–’25)
P/B
Graham’s price gate

Graham capped the multiple at 15×; Buffett and Munger let that rule go: a wonderful business can deserve 50× if the thesis holds. The gate marks the bargain-hunter's floor.

Against a high-grade bond: Graham’s yardstick bond yield%

Prefilled with the 10-year Treasury (4.71%, as of Aug 18, 2026). Edit it for today’s exact figure, or a AAA corporate yield.

Graham measured a stock against the bond you could own instead, the heart of his margin of safety. Enter a price above to weigh the owner-earnings yield against this bond.

Owner earnings ($143M) on 60M shares outstanding, per the 10-Q cover, as of 2026-07-30; net cash $56M. The base opens on the through-cycle figure (the latest year sits off the record’s own median, and Graham’s averaging cuts both ways); clear Normalize to use the year as filed. Net of stock comp treats option pay as the expense it is. The dials set the multiple a growth belief justifies; the price, and every dollar on this page, is yours.

Cite: Owner Scorecard, "Vanda Pharmaceuticals Inc. (VNDA), the owner's record," https://ownerscorecard.com/c/VNDA, data as of 2026-08-17.

Manual order: ← VMI its page in the Manual VNO →

Industry order: ← UTHR the Pharmaceuticals chapter VRDN →